StockData
Aurinia Pharmaceuticals Inc. logo

Aurinia Pharmaceuticals Inc. (AUPH) stock

AUPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 13/3058% below fair value
$15.40−0.08 (-0.52%)

Close on Nov 17, 2026Market cap $2.06BP/E 6.7Yield –

Aurinia Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Aurinia Pharmaceuticals's operating cash flow for the twelve months ending Sep 30, 2026 was $177.16M, up 47.5% year over year. For fiscal 2025 it was $135.66M, up 205.6% from the year before. The highest annual figure on record is $135.66M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$135.66M+205.6%
FY2024Dec 31, 2024$44.39M–
FY2023Dec 31, 2023-$33.46M–
FY2022Dec 31, 2022-$79.53M–
FY2021Dec 31, 2021-$157.69M–
FY2020Dec 31, 2020-$69.86M–
FY2019Dec 31, 2019-$63.59M–
FY2018Dec 31, 2018-$51.61M–
FY2017Dec 31, 2017-$41.17M–
FY2016Dec 31, 2016-$18.71M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$46.37M+4.3%
Q2 FY2026Jun 30, 2026$52.57M+18.8%
Q1 FY2026Mar 31, 2026$32.56M+2404.6%
Q4 FY2025Dec 31, 2025$45.67M+51.7%
Q3 FY2025Sep 30, 2025$44.45M+161.0%
Q2 FY2025Jun 30, 2025$44.24M+179.2%
Q1 FY2025Mar 31, 2025$1.30M–
Q4 FY2024Dec 31, 2024$30.11M+110.4%
Q3 FY2024Sep 30, 2024$17.03M–
Q2 FY2024Jun 30, 2024$15.84M–
Q1 FY2024Mar 31, 2024-$18.60M–
Q4 FY2023Dec 31, 2023$14.31M+37.0%
Q3 FY2023Sep 30, 2023-$13.28M–
Q2 FY2023Jun 30, 2023-$2.83M–
Q1 FY2023Mar 31, 2023-$31.67M–
Q4 FY2022Dec 31, 2022$10.45M–
Q3 FY2022Sep 30, 2022-$15.36M–
Q2 FY2022Jun 30, 2022-$27.87M–
Q1 FY2022Mar 31, 2022-$46.75M–
Q4 FY2021Dec 31, 2021-$25.92M-909.1%
Q3 FY2021Sep 30, 2021-$40.25M–
Q2 FY2021Jun 30, 2021-$37.98M–
Q1 FY2021Mar 31, 2021-$53.54M–
Q4 FY2020Dec 31, 2020$3.20M–
Q3 FY2020Sep 30, 2020-$28.42M–
Q2 FY2020Jun 30, 2020-$22.04M–
Q1 FY2020Mar 31, 2020-$22.61M–

More Aurinia Pharmaceuticals figures

See a number that looks wrong?